Osiris Therapeutics strikes deal to fund biotechnology research

March 17, 1998|BY A SUN STAFF WRITER

Baltimore-based Osiris Therapeutics Inc. said yesterday that it has struck an alliance with an Italian research group to develop treatments to help connective tissue cells regenerate quickly after chemotherapy, bone injuries and connective tissue disorders.

Under the agreement, Osiris said it will supply $1 million in research funding to the Center for Advanced Biotechnology at the Institute for Cancer Research and the University of Genoa, Italy. Osiris said the alliance will seek to build on research by Dr. Ranieri Cancedda at the Center for Advanced Biotechnology.

The three-year research alliance will focus on the role of progenitor cells, called mesenchymal stem cells, in regenerating connective tissues, including bone, cartilage, tendons, ligaments and muscles.

Osiris said that the initial goal of the research effort will be to determine the role of stem cells in regenerating connective tissues after they are damaged by chemotherapy, radiation or bone marrow disorders.

Osiris said it holds worldwide marketing rights to regeneration technologies or treatments developed from the alliance.

Osiris currently is attempting to develop drugs and other treatments which would help connective tissue stem cells damaged by injury, aging or degenerative diseases.

Pub Date: 3/17/98

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.